Citation

Phillips DP, Gao W, Yang Y, Zhang G, Lerario IK, Lau TL, Jiang J, Wang X, Nguyen DG, Bhat BG, Trotter C, Sullivan H, Welzel G, Landry J, Chen Y, Joseph SB, Li C, Gordon WP, Richmond W, Johnson K, Bretz A, Bursulaya B, Pan S, McNamara P, Seidel HM.: Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy. J Med Chem, Volume 57 (8), 2014

Authors

Bhat BG, Bretz A, Bursulaya B, Chen Y, Gao W, Gordon WP, Jiang J, Johnson K, Joseph SB, Landry J, Lau TL, Lerario IK, Li C, McNamara P, Nguyen DG, Pan S, Phillips DP, Richmond W, Seidel HM., Sullivan H, Trotter C, Wang X, Welzel G, Yang Y, Zhang G

Journal

J Med Chem

Year

2014

DOI

10.1021/jm401731q

PubMed

24666203

Machine-readable

REST APIRDF